Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | WNT3A | P56704 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7366656 | 0.94 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL10316359 | 0.89 | GPR119 (0.69) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL29680840 | 0.89 | MEN1 (0.54) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL14711349 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL27197478 | 0.87 | GPR119 (0.51) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL31544598 | 0.87 | MAPT (0.61) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL15727931 | 0.85 | GPR119 (0.53) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL29680690 | 0.85 | CYP11B2 (0.50) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL5573222 | 0.85 | MAPT (0.76) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL25217296 | 0.85 | VEGFA (0.52) | SMN1; SMN2MAPTLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1187592-A4 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2002-11-06 | — | — | EP | claimed |
| EP-1187592-A2 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2002-03-20 | — | — | EP | claimed |
| WO-2000072801-A2 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-12-07 | — | — | WO | claimed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-20240269298-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-08-15 | — | — | US | disclosed |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| EP-4332100-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| CN-117425646-A | Phosphono derivative, composition thereof and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-01-19 | — | — | CN | disclosed |
| EP-3573961-B1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2023-10-25 | — | — | EP | disclosed |
| EP-3573961-B1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2023-10-25 | — | — | EP | disclosed |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-10987351-B2 | RORgamma modulators and uses thereof | GENFIT (FR) | 2021-04-27 | — | — | US | disclosed |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2020-04-30 | — | — | US | disclosed |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2020-04-30 | — | — | US | disclosed |
| WO-2018138354-A1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2018-08-02 | — | — | WO | disclosed |
| EP-1107756-A4 | NOVEL ISOXAZOLINONE ANTIBACTERIAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20020094984-A1 | Novel isoxazolinone antibacterial agents | SNYDER LAWRENCE B (US) | 2002-07-18 | — | — | US | disclosed |
| US-6420349-B1 | POTENT ANTIBIOTIC ACTIVE AGAINST GRAM-POSITIVE BACTERIA; ANIMAL FEED;FOOD PRESERVATIVES; WATERBASED PAINTS; WHITE WATER OF PAPER MILLS; DISINFECTANTS FOR MEDICAL AND DENTAL EQUIPMENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-16 | — | — | US | disclosed |
| EP-1107756-A1 | NOVEL ISOXAZOLINONE ANTIBACTERIAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000010566-A1 | NOVEL ISOXAZOLINONE ANTIBACTERIAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269298-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | EGFR, BLK, CSNK1A1L | SMN1; SMN2 4694/4885MAPT 2478/4885LMNA 1804/4885 |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | SMN1; SMN2 2113/4885MAPT 3617/4885LMNA 1887/4885 |
| US-20020094984-A1 | Novel isoxazolinone antibacterial agents | RPS4X, RPS4Y1, CYP51A1 | SMN1; SMN2 2607/4885MAPT 4521/4885LMNA 3819/4885 |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | SMN1; SMN2 2113/4885MAPT 3617/4885LMNA 1887/4885 |
| US-10987351-B2 | RORgamma modulators and uses thereof | RORB, RORC, RORA | SMN1; SMN2 4792/4885MAPT 4111/4885LMNA 4465/4885 |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | SMN1; SMN2 2113/4885MAPT 3617/4885LMNA 1887/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | SMN1; SMN2 2142/4885MAPT 3834/4885LMNA 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.